Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 22, 2025 06:12 ET | Source: Boehringer Ingelheim Limited

JASCAYD® (nerandomilast) approved in China for the treatment of idiopathic pulmonary fibrosis (IPF)

"Not intended for US or UK audiences."Ingelheim, GermanyApproval is based on results from Phase III FIBRONEER™-IPF trial, which showed statistically significant improvements in the absolute change...
October 15, 2025 07:00 ET | Source: Transpire Bio

Transpire Bio Granted Orphan Drug Designation by the U.S. FDA For Two Rare Diseases

Transpire Bio today announced that the U.S. FDA has granted orphan drug designation (ODD) for two of its products in development.
October 09, 2025 06:05 ET | Source: Boehringer Ingelheim Limited

U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade

Ingelheim, Germany/Ridgefield, Connecticut, U.S. Idiopathic pulmonary fibrosis (IPF) is a progressive disease, causing a continuous decline in lung function.1Approval is based on results from two...
September 29, 2025 02:05 ET | Source: Boehringer Ingelheim Limited

Pooled data presented at ERS: nerandomilast monotherapy linked to nominally significant reduction in risk of death in IPF and PPF

A new pooled analysis of the FIBRONEER™-IPF and FIBRONEER™-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without...
September 11, 2025 08:45 ET | Source: GRI Bio, Inc.

GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

No decline in lung function observed at 6-week interim analysis builds upon positive safety and biomarker data Phase 2a study fully enrolled; Topline data on track for Q3 2025 Currently available...
September 05, 2025 04:04 ET | Source: Research and Markets

Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market Forecasts Report 2025-2030 | Boehringer Ingelheim and FibroGen Lead by Driving Innovations in Pharmacological and Diagnostic Advancements

Dublin, Sept. 05, 2025 (GLOBE NEWSWIRE) -- The "Idiopathic Pulmonary Fibrosis Diagnostic And Treatment Market - Forecasts from 2025 to 2030" report has been added to ResearchAndMarkets.com's...
July 31, 2025 09:00 ET | Source: GRI Bio, Inc.

GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Biomarkers at 6-week interim analysis show a positive impact on fibrogenesis, fibrolysis and potentially the initiation of a repair response The Independent Data Monitoring Committee (IDMC) has...
July 01, 2025 08:45 ET | Source: GRI Bio, Inc.

GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival 2- and 6-week interim...
June 26, 2025 08:00 ET | Source: GRI Bio, Inc.

GRI Bio’s GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

The Independent Data Monitoring Committee (“IDMC”) has recommended to continue the study as planned as there are no safety concerns demonstrated in the data reviewed Interim results to date...
May 19, 2025 12:15 ET | Source: Boehringer Ingelheim Limited

Global phase III trials demonstrate that nerandomilast slowed lung function decline in IPF and PPF, with similar discontinuation rates to placebo

Nerandomilast, an investigational agent, met the primary endpoint of both phase III trials, FIBRONEER™-IPF and FIBRONEER™-ILD, significantly reducing the decline in forced vital capacity (FVC) [mL] by...